Sutro Biopharma’s (STRO) Outperform Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Sutro Biopharma (NASDAQ:STRO) in a research note issued to investors on Thursday morning,Benzinga reports. Wedbush currently has a $60.00 price objective on the stock.

Other analysts have also issued research reports about the company. Citizens Jmp upped their target price on Sutro Biopharma from $35.00 to $41.00 and gave the stock a “market outperform” rating in a report on Thursday, April 23rd. HC Wainwright increased their target price on Sutro Biopharma from $28.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, May 15th. Mizuho set a $50.00 price target on Sutro Biopharma and gave the company an “outperform” rating in a report on Thursday, April 30th. Lifesci Capital raised Sutro Biopharma to a “strong-buy” rating in a research report on Friday, May 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $47.30.

Sutro Biopharma Stock Performance

Shares of STRO opened at $20.48 on Thursday. The company has a 50 day moving average price of $26.86 and a 200-day moving average price of $25.95. Sutro Biopharma has a fifty-two week low of $7.15 and a fifty-two week high of $43.85. The stock has a market capitalization of $339.56 million, a PE ratio of -1.86 and a beta of 1.55.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($2.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.19) by ($0.14). The firm had revenue of $9.84 million for the quarter, compared to analysts’ expectations of $11.96 million. Equities research analysts forecast that Sutro Biopharma will post -8.83 EPS for the current year.

Institutional Investors Weigh In On Sutro Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of STRO. State of Tennessee Department of Treasury acquired a new stake in Sutro Biopharma in the fourth quarter valued at approximately $86,000. Sigma Planning Corp acquired a new position in shares of Sutro Biopharma during the first quarter worth $312,000. Bank of America Corp DE lifted its holdings in shares of Sutro Biopharma by 348.1% during the 1st quarter. Bank of America Corp DE now owns 18,873 shares of the company’s stock valued at $470,000 after purchasing an additional 14,661 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Sutro Biopharma during the 4th quarter valued at $265,000. Finally, Stempoint Capital LP purchased a new stake in shares of Sutro Biopharma during the 1st quarter valued at $580,000. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Trending Headlines about Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $50 price target, implying substantial upside from recent levels. The firm raised its EPS forecasts for fiscal 2027 through 2030, including improving estimates for fiscal 2028, 2029 and 2030. HC Wainwright analyst estimates
• Positive Sentiment: Wedbush reaffirmed its Outperform rating and $60 price target, while Citizens JMP retained a Market Outperform rating despite reducing its target to $34. These targets indicate analysts still see meaningful potential if Sutro’s pipeline and commercial prospects develop as expected. Analyst rating updates
• Neutral Sentiment: A market roundup described analysts as having conflicting views on Sutro and other healthcare companies, highlighting a divergence between optimistic ratings and concerns about ongoing losses and execution risk. Analysts have conflicting sentiments on healthcare companies
• Negative Sentiment: HC Wainwright cut its Q3 and Q4 2026 EPS estimates to losses of $2.38 and $2.46, respectively, from $2.32 previously for both periods. Although later-year estimates improved, the revisions reinforce expectations for continued heavy cash burn and losses.
• Negative Sentiment: Sutro’s latest quarterly results missed expectations: adjusted loss per share was $2.33 versus the consensus loss estimate of $2.19, while revenue of $9.84 million fell short of the $11.96 million forecast. The disappointing results likely contributed to the selling pressure and elevated trading volume.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.